ArticleAAPS PharmSciTech2026
Development of Biocompatible Nanocarriers for Antiretrovirals Based on Polylactide and Chitosan.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although numerous, effective antiviral therapies are in clinical use, there is a significant demand for novel, improved drug delivery systems (DDS) to enhance the biological and pharmacokinetic properties of administered drugs. Nanostructured carrier systems are increasingly recognized as promising candidates; however, their development is still in its infancy. Herein, we have developed a biocompatible system composed of polylactide and chitosan, loaded with tenofovir alafenamide (TAF) as an antiretroviral drug. Our nanoparticles (NPs) were able to release TAF for 21 days, depending on the chitosan content in their matrix. Moreover, the NPs were not cytotoxic and showed high antiviral activity in an in vitro HIV infection assay. Most importantly, the effectiveness of the selected nanoformulations was comparable to that of free TAF (IC
Indexed as
Identifiers
41807745What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.